Search
for
Sort by
Research 901–930 of 1000+
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Cutaneous Manifestations of COVID-19: A Brief Review of a Possible Diagnostic Tool
- A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Comparison of clinical characteristics among different time of disease onset in patients with systemic lupus erythematosus patients
- THU0349 Early Symptoms of Systemic Lupus Erythematosus (SLE) Recalled by 337 SLE Patients: Table 1.
- Pathologies of the skin and its appendages in endocrine diseases
- Esssentials of Systemic Lupus Erythematosus
- Thallium poisoning: Clinical observations through two outbreaks in Basrah
- Philological Obfuscation
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Phenotypic variation in biotinidase deficiency
- Cutaneous lupus erythematosus: a review
- The spectrum of cutaneous manifestations in lupus erythematosus—the Italian experience
- Partial biotinidase deficiency: Clinical and biochemical features
- Lead, Mercury, and Arsenic Poisoning Due to Topical Use of Traditional Chinese Medicines
- Clinical and immunological manifestations in 151 SLE patients living in Dubai
- Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Pubic Hair Removal—Pearls and Pitfalls
- Six-year Retrospective Review of Drug Reaction with Eosinophilia and Systemic Symptoms
- Associated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study
- Toxic shock syndrome: Recent developments in pathogenesis
- Systemic Lupus Erythematosus
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Vitamin A toxicity: When one a day doesn't keep the doctor away
- Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations
- Inhibition of 3‐methylcrotonyl‐CoA carboxylase explains the increased excretion of 3‐hydroxyisovaleric acid in valproate‐treated patients